antibody

Goat anti-VHL Antibody

MBS421293

0.1 mg

290 USD

polyclonal

goat

nonconjugated

human, mouse, rat, dog

western blot, ELISA, enzyme immunoassay

Antibody

Goat anti-VHL Antibody

VHL

VHL; von Hippel-Lindau tumor suppressor; HRCA1; RCA1; VHL1; elongin binding protein; von Hippel-Lindau syndrome; VHL; von Hippel-Lindau tumor suppressor; HRCA1; RCA1; VHL1; elongin binding protein; von Hippel-Lindau syndrome

von Hippel-Lindau disease tumor suppressor isoform 1; Von Hippel-Lindau disease tumor suppressor; von Hippel-Lindau disease tumor suppressor; protein G7; elongin binding protein; von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase; Protein G7; pVHL

VHL

VHL; VHL; RCA1; VHL1; pVHL; HRCA1

VHL_HUMAN

Polyclonal

Goat

Human, Mouse, Rat, Dog

213

RSLVKPENYRRLD

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide

Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul

Aliquot and store at -20 degree C. Minimize freezing and thawing.

Peptide ELISA (EIA), Western Blot (WB), ELISA (EIA)

Western Blot: Approx 17kDa band observed in Human Ovary and Testis lysates and also in lysates of Mouse and Rat Testis and Brain and of all human and mouse cell lines tested (calculated MW of 19.7kDa according to NP_937799.1). Recommended concentration: 0.01-0.03ug/ml. Peptide ELISA: antibody detection limit dilution 1:128000. Enzyme immunoassay: Sandwich-type ELISA with increasing amount of recombinant VHL captured by a rabbit antibody. Recommended reporter concentration: 1.5-3ug/ml

Epitope: Internal Region. Immunogen: Peptide with sequence C-RSLVKPENYRRLD, from the internal region of the protein sequence according to NP_000542.1; NP_937799.1. Corresponding Immunizing Peptide: Catalog #MBS425534

Important Note: This antibody is expected to recognise both reported isoforms (NP_000542.1 and NP_937799.1).

4507891

NP_000542.1

NM_000551.3

18,532 Da

Adaptive Immune System Pathway 366160!!Antigen Processing: Ubiquitination Proteasome Degradation Pathway 366162!!Cellular Response To Hypoxia Pathway 645259!!Cellular Responses To Stress Pathway 645258!!Class I MHC Mediated Antigen Processing Presentation Pathway 366161!!ECV Complex Pathway 413450!!ECV Complex Pathway 890606!!HIF-1 Signaling Pathway 695200!!HIF-2-alpha Transcription Factor Network Pathway 137956!!Hypoxic And Oxygen Homeostasis Regulation Of HIF-1-alpha Pathway 138056

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008]

0.1 mg

290 USD